High blood pressure (BP) has cropped up as a prominent reason for worldwide untimely deaths. In India also numbers are increasing sharply & becoming a crucial risk factor for cardiovascular diseases (CVD). Significant heart care demands regular BP measurements. As per American heart association recommendations, office BP readings are used to start antihypertensive medicines.
Provide only BP snapshot report
Chances of showing falsely manipulated high or low BP value
No throughout-the-day BP variation data availability
Not able to monitor the antihypertensive medication effect on the BP variation
What is Ambulatory BP measurement (ABPM)?
It is a more accurate BP measuring standard which offers 24 hours reading (every 15-30 mins), accesses BP variability along with diurnal rhythmic changes, nocturnal dipping & morning surge, and predicts potential heart disease risk & antihypertensive drug impact.
Increased ABPV is a risk factor for CVD & cognitive dysfunction. Not offers details more than ABP mean comparisons between systolic and diastolic ABP. Thorough work is required to find the right comparison between day & night ABPV.
The mean values of ABPV show stability. Contextual factors like eating, and walking affects ABPV values. Test-retest data of more diverse activities is limited. BP varies with each heartbeat & shows the change in a short duration. ABPV only calculates the Standard deviation (SD) of all BP observations during the measurement period & ignores measurement order leading to very different patterns of BP changes with the same SD variability. Average real variability allows getting absolute differences of consecutive measurements to find out the right measurement variability.
High ABPV predictors are age, ethnicity, mental disorders (depression, anger, pessimistic & anxious nature), low social support, stress, dietary changes, physical inactivity & environmental conditions.
The mean BP & ABPV gets affected & CVD events reduce by using BP-lowering medicines like β-blockers, calcium-channel blockers, and diuretics. In clinical practice, it is still not established well. Lifestyle changes like increased physical activity, healthy eating habits, stress management & right sleep hygiene improve ABPV values further. Physicians can use early identification of high ABPV as a supportive solution to prevent heart disease onset & underlying disease.
Examining contextual variables and momentary perceptions relations with ABP levels
Determining causes of ABP variation & how higher variability predicts CVD
Establishing the relationship between systolic ABPV and C-reactive protein (a key marker of inflammation), high ABPV & CVD risk. Finding the link between the HPA axis regulating hormones like adrenal glands, and estrogen with ABPV
With the help of ABPV, the development & prognosis of CVD can be understood well. This can assure superior proactive CVD prevention & treatment quality. It is mandatory to enhance ABP monitoring usage in clinical setup & analyse ABPV values.
1.
Potential targets for treating the most common type of liver cancer in children have been identified by a collaborative study.
2.
Study identifies new approach to protect the brain during radiation therapy
3.
While most cancer screenings won't prolong lives, there are still good reasons to continue screening.
4.
Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.
5.
Radiation therapy for patients with breast cancer
1.
Radiation in Oncology: Advances, Applications, and Accessibility
2.
The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review
3.
Cracking Oncology Drug Resistance: New Strategies to Overcome Challenges in Modern Cancer Therapy
4.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
5.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
3.
Navigating the Complexities of Ph Negative ALL - Part XIII
4.
Navigating the Complexities of Ph Negative ALL - Part IV
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation